NYSE · Healthcare
Penumbra Inc (PEN)
As-reported financials and recent SEC filings for Penumbra Inc, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$1.40B
Net income
$177.7M
Net margin
12.7%
Diluted EPS
$4.52
ROE
12.4%
P/E (TTM)
73.0×
Market cap
$12.45B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.40B | $1.19B | $1.06B | $847.1M | $747.6M |
| Gross profit | $942.4M | $755.0M | $682.6M | $535.2M | $475.4M |
| Operating income | $189.2M | $9.3M | $73.6M | $6.1M | $-7.5M |
| Net income | $177.7M | $14.0M | $91.0M | $-2.0M | $5.3M |
| Diluted EPS | $4.52 | $0.36 | $2.32 | $-0.05 | $0.14 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-22
View on EDGAR →SD2026-05-29
View on EDGAR →42026-05-21
View on EDGAR →4252026-05-07
View on EDGAR →8-K2026-05-07
View on EDGAR →10-Q2026-05-06
View on EDGAR →8-K2026-05-06
View on EDGAR →SCHEDULE 13G2026-04-30
View on EDGAR →Go deeper on PEN
Search Penumbra Inc’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.